Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.

Patient Prefer Adherence · 2014 · PMC4144933 · PMID 25170258

Europe PMC DOI

hedged sentence

0.0970

closest p · 1.9× alpha

0.0970

boldest claim

The sentences

showed a trendP =0.097so close (0.05 < p ≤ 0.1)

39 Among secondary clinical outcomes, median time to first relapse from baseline and the proportion of relapse-free patients over 2 years showed a trend favoring GA over placebo (287 versus 198 days, P =0.097; 33.6% versus 27.0%, P =0.098; respectively).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.